| Description | The antibody Cv2.3194 is a human IgG that binds to SARS-CoV-2 Spike S1. Cv2.3194 were fully active against VOCs Alpha, Beta, Gamma, and Delta, and still strongly blocked Omicron BA.1 and BA.2 infection in vitro. The anti-RBD antibody blocks the interaction of the ACE2 ectodomain with RBD proteins fromSARS-CoV-2 variants of concern (VOCs). This antibody has been tested by Enzyme-linked immunosorbent assay, Flow cytometry, Surface plasmon resonance and Neutralization assay. |
| Clonality | Monoclonal |
| Host Species | Human |
| Target Species | SARS-CoV-2 (Alpha, Beta, Gamma, Delta, Omicron BA.1 and BA.2) |
| Epitope | Receptor binding motif (RBM) |
| Affinity | 1.20 nM |
| Expression Species | HEK293F or CHO cell line |
| Conjugation | Unconjugated |
| Purity | >95% |
| Endotoxin | <1 EU/mg |
| Form | Liquid |
| Purification | Protein A purified |
| Sterility | 0.2 μM filtered |
| Formulation | PBS, pH 7.4 |
| Preservation | No preservatives |
| Stabilizer | No stabilizers |
| Storage | Store at 4°C within one or two weeks. Store at -20°C for long term. Avoid repeated freeze/thaw cycles. Refer to the COA file for specifics. |
| Application | ELISA; FC; Neut; SPR |
| Application Notes | ELISA: 1/4000 Flow cytometry: 1 µg/mL Neutralization assay: IC50 = 8.8 ng/mL (to S-Fuse) Surface plasmon resonance (SPR): 10 μg/mL |
| ELISA | Enzyme-Linked Immunosorbent Assay Protocol |
| WB | Western Blot Protocol |
| FC | Flow Cytometry Protocol |
| Target | SARS-CoV-2 S1 |
| Alternative Name | Severe acute respiratory syndrome coronavirus 2 Spike S1 |
| Research Area | Coronavirus Disease 2019 |
| Related Disease | Coronavirus Disease 2019 |
